Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis

Gastroenterology

Volumn 124, Issue 1, 2003, Pages 47-56

  Corley, Douglas A ^a,b,e   Kerlikowse, Karla ^b,c   Verma, Rajiv ^b   Buffler, Patricia ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADENOCARCINOMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; DRUG SCREENING; ESOPHAGUS CANCER; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS;

EID: 0037219463     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2003.50008     Document Type: Article

References (85)

1. McKinney A, Sharp L, Macfarlane GJ, Muir CS. Oesophageal and gastric cancer in Scotland 1960-90. Br J Cancer 1995;71:411-415.
2. Hansson LE, Sparaen P, Nyraen O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer 1993;54:402-407.
3. Hansson LE, Sparaen P, Nyraen O. Increasing incidence of carcinoma of the gastric cardia in Sweden from 1970 to 1985. Br J Surg 1993;80:374-377.
4. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.
5. Hansen S, Wiig JN, Giercksky KE, Tretli S. Esophageal and gastric carcinoma in Norway 1958-1992: Incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer 1997;71:340-344.
6. Lord RV, Law MG, Ward RL, Giles GG, Thomas RJ, Thursfield V. Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol 1998;13:356-362.
7. Thomas RJ, Lade S, Giles GG, Thursfield V. Incidence trends in oesophageal and proximal gastric carcinoma in Victoria. Aust N Z J Surg 1996;66:271-275.
8. Levi F, La Vecchia C. Adenocarcinoma of the esophagus in Switzerland [letter; comment]. JAMA 1991;265:2960.
9. Yang PC, Davis S. Incidence of cancer of the esophagus in the US by histologic type. Cancer 1988;61:612-617.
10. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993;104:510-513.
11. Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990;62:440-443.
12. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia [see comments]. JAMA 1991;265:1287-1289.
13. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: An update [letter]. JAMA 1993;270:1320.
14. Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on esophageal carcinoma. Cancer 1996;78:1820-1828.
15. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998;93:1028-1032.
16. Heath CW Jr, Thun MJ, Greenberg ER, Levin B, Marnett LJ. Nonsteroidal anti-inflammatory drugs and human cancer. Report of an interdisciplinary research workshop. Cancer 1994;74:2885-2888.
17. Vainio H, Morgan G. NSAIDs, Barrett's oesophagus and adenocarcinoma prevention [letter]. Eur J Cancer Prev 1997;6:200.
18. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-246.
19. IARC. Non-steroidal anti-inflammatory drugs. In: IARC Handbooks of Cancer Prevention. Vol. 1. Lyon, France: IARC Press, 1997.
20. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-266.
21. Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal anti-inflammatory drugs. Cancer 2002;94:950-963.
22. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
23. Ratnasinghe D, Tangrea J, Roth MJ, Dawsey S, Hu N, Anver M, Wang QH, Taylor PR. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; an immunohistochemical survey. Anticancer Res 1999;19:171-174.
24. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001;96:990-996.
25. Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM, Lippman SM. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res 2001;61:4879-4884.
26. el Attar TM, Lin HS. Prostaglandin synthesis by squamous carcinoma cells of head and neck, and its inhibition by non-steroidal anti-inflammatory drugs. J Oral Pathol 1987;16:483-487.
27. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000;30:3-21.
28. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002;33:708-714
29. Kawabe A, Shimada Y, Uchida S, Maeda M, Sato F, Itami A, Imamura M. Expression of cyclooxygenase-2 is associated with carcinogenesis of the lower part of thoracic esophageal squamous cell carcinoma and p53 expression. Oncology 2002;62:46-54.
30. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000;118:487-496.
31. Kandil HM, Tanner G, Smalley W, Halter S, Radhika A, Dubois RN. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001;46:785-789.
32. Morgan GP, Williams JG. Inflammatory mediators in the oesophagus. Gut 1994;35:297-298.
33. Chang-Claude JC, Wahrendorf J, Liang QS, Rei YG, Munoz N, Crespi M, Raedsch R, Thurnham DI, Correa P. An epidemiological study of precursor lesions of esophageal cancer among young persons in a high-risk population in Huixian, China. Cancer Res 1990;50:2268-2274.
34. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.
35. The Cochrane Controlled Trials Register. The Cochrane Library. Volume 4. Oxford: Update Software, updated quarterly, 2001.
36. The Web of Science. Volume 2001. www.webofscience.com.
37. Greenland S. Invited commentary: A critical look at some popular meta-analytic methods. Am J Epidemiol 1994;140:290-296.
38. Poole C, Greenland S. Random-effects meta-analyses are not always conservative. Am J Epidemiol 1999;150:469-475.
39. Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. Oxford University Press, 2000.
40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-188.
41. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, Dubrow R, Schoenberg JB, Mayne ST, Farrow DC, Ahsan H, West AB, Rotterdam H, Niwa S, Fraumeni JF Jr. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-155.
42. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282:1054-1060.
43. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-46.
44. Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983;309:1358-1361.
45. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clin Trials 1996;17:1-12.
46. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412.
47. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals [see comments]. JAMA 1994;272:125-128.
48. Imperiale TF, Birgisson S. Somatostatin or octreotide compared with H2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: A meta-analysis. Ann Intern Med 1997;127:1062-1071.
49. Gerbarg ZB, Horwitz RI. Resolving conflicting clinical trials: Guidelines for meta-analysis. J Clin Epidemiol 1988;41:503-509.
50. Imperiale TF. Meta-analysis: When and how. Hepatology 1999;29:26S-31S.
51. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research. Principles and Quantitative Methods. New York: Van Nostrand Reinhold, 1982.
52. Kendall MG, Gibbons JD. Rank Correlation Methods. New York: Oxford University Press, 1990.
53. Garidou A, Tzonou A, Lipworth L, Signorello LB, Kalapothaki V, Trichopoulos D. Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population. Int J Cancer 1996;68:295-299.
54. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-1327.
55. Suleiman UL, Harrison M, Britton A, McPherson K, Bates T. H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: A case-control study. Eur J Cancer Prev 2000;9:185-191.
56. Peleg I, Cotsonis GA, Clark WS, Wilcox CM. Nonsteroidal anti-inflammatory drugs (NSAID's) use and the risk of subsequent cancer of the upper gastrointestinal tract (UGI) [abstract]. J Investig Med 1995;43:251A.
57. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database. BMJ 2000;320:1642-1646.
58. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995;76:1116-1119.
59. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000;9:119-123.
60. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr, Blot WJ. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
61. Cheng KK, Sharp L, McKinney PA, Logan RF, Chilvers CE, Cook-Mozaffari P, Ahmed A, Day NE. A case-control study of oesophageal adenocarcinoma in women: A preventable disease. Br J Cancer 2000;83:127-132.
62. Sharp L, Chilvers CE, Cheng KK, McKinney PA, Logan RF, Cook-Mozaffari P, Ahmed A, Day NE. Risk factors for squamous cell carcinoma of the oesophagus in women: A case-control study. Br J Cancer 2001;85:1667-1670.
63. Sajadieh A, Wendelboe O, Hansen JF, Mortensen LS. Nonsteroidial anti-inflammatory drugs after acute myocardial infarction. DAVIT Study Group. Danish Verapamil Infarction Trial. Am J Cardiol 1999;83:1263-1265, A9.
64. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-2288.
65. Jick SS. The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam. Pharmacotherapy 2000;20:741-744.
66. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000;11:382-387.
67. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-1596.
68. Pasricha PJ, Bedi A, O'Connor K, Rashid A, Akhtar AJ, Zahurak ML, Piantadosi S, Hamilton SR, Giardiello FM. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995;109:994-998.
69. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-1619.
70. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635-639.
71. Rubio CA, Wallin B, Ware J, Sveander M, Duvander A. Effect of indomethacin in autotransplanted colonic tumors. Dis Colon Rectum 1989;32:488-491.
72. Rubio CA. Further studies on the therapeutic effect of indomethacin on esophageal tumors. Cancer 1986;58:1029-1031.
73. Rubio CA. Antitumoral activity of indomethacin on experimental esophageal tumors. J Natl Cancer Inst 1984;72:705-707.
74. Tsibouris P, Hendricksce MT, Zissis M, Isaacs PE. NSAIDs do not protect patients with Barrett oesophagus from adenocarcinoma development (abstr). Gastroenterology 2001;120(Suppl 1):A595.
75. Schnell T, Sontag SJ, Chejfec G, Ulasevich A, Levine G, Reid S, Karpf J, Brand L. Does aspirin (ASA) or NSAID use influence the development of esophageal adenocarcinoma (ADCA)? (abstr) Gastroenterology 1997;112:A652.
76. Sample DA, Sinicrope PS, Wargovich MJ, Sinicrope FA. Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2002;11:281-285.
77. Patterson RE, Neuhouser ML, White E, Hunt JR, Kristal AR. Cancer-related behavior of vitamin supplement users. Cancer Epidemiol Biomarkers Prev 1998;7:79-81.
78. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817.
79. Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol 1994;21:403-410.
80. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2-8.
81. Brown LM, Silverman DT, Pottern LM, Schoenberg JB, Greenberg RS, Swanson GM, Liff JM, Schwartz AG, Hayes RB, Blot WJ, Hoover RN. Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: Alcohol, tobacco, and socioeconomic factors. Cancer Causes Control 1994;5:333-340.
82. Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL, Chow WH, Rotterdam H, West AB, Dubrow R, Stanford JL, Mayne ST, Farrow DC, Niwa S, Blot WJ, Fraumeni JF Jr. Tobacco, alcohol and socioeconomic status and adenocarcinomas of the esopha gus and gastric cardia [see comments]. J Natl Cancer Inst 1997;89:1277-1284.
83. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
84. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? [see comments]. Gastroenterology 2000;119:333-338.
85. Taylor PR, Li B, Dawsey SM, Li JY, Yang CS, Guo W, Blot WJ. Prevention of esophageal cancer: The nutrition intervention trials in Linxian, China. Linxian Nutrition Intervention Trials Study Group. Cancer Res 1994;54:2029s-2031s.